Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,204,172
  • Shares Outstanding, K 56,331
  • Annual Sales, $ 738,260 K
  • Annual Income, $ 48,890 K
  • EBIT $ 55 M
  • EBITDA $ 151 M
  • 60-Month Beta 1.15
  • Price/Sales 9.16
  • Price/Cash Flow 35.12
  • Price/Book 3.21

Options Overview Details

View History
  • Implied Volatility 53.02% (+4.04%)
  • Historical Volatility 39.33%
  • IV Percentile 73%
  • IV Rank 34.88%
  • IV High 84.92% on 04/07/25
  • IV Low 35.94% on 08/14/25
  • Expected Move (DTE 10) 10.63 (8.50%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 11
  • Volume Avg (30-Day) 294
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 8,472
  • Open Int (30-Day) 8,038
  • Expected Range 114.48 to 135.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.38
  • Number of Estimates 5
  • High Estimate 0.41
  • Low Estimate 0.37
  • Prior Year 0.39
  • Growth Rate Est. (year over year) -2.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.06 +5.92%
on 03/09/26
145.43 -14.01%
on 02/11/26
-18.00 (-12.59%)
since 02/10/26
3-Month
118.06 +5.92%
on 03/09/26
175.77 -28.85%
on 01/06/26
-38.75 (-23.65%)
since 12/10/25
52-Week
102.96 +21.46%
on 04/07/25
175.77 -28.85%
on 01/06/26
-11.94 (-8.71%)
since 03/10/25

Most Recent Stories

More News
3 Profitable Stocks We Keep Off Our Radar

3 Profitable Stocks We Keep Off Our Radar

DHI : 146.65 (-0.70%)
RGEN : 125.27 (-2.05%)
NMRK : 14.59 (+0.69%)
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know

AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know

AMN : 20.59 (-0.19%)
EVH : 3.00 (-1.32%)
RGEN : 125.27 (-2.05%)
AMPH : 19.51 (+1.56%)
RDNT : 60.61 (-2.76%)
Repligen Corporation to Present at Upcoming March Conferences

WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating...

RGEN : 125.27 (-2.05%)
3 Healthcare Stocks We’re Skeptical Of

3 Healthcare Stocks We’re Skeptical Of

TNDM : 21.16 (+1.34%)
RGEN : 125.27 (-2.05%)
SEM : 16.25 (unch)
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead

3 Reasons to Avoid RGEN and 1 Stock to Buy Instead

RGEN : 125.27 (-2.05%)
Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know

Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know

PRVA : 23.04 (-1.12%)
RGEN : 125.27 (-2.05%)
RDNT : 60.61 (-2.76%)
Repligen: Q4 Earnings Snapshot

Repligen: Q4 Earnings Snapshot

RGEN : 125.27 (-2.05%)
Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations

Repligen (NASDAQ:RGEN) Exceeds Q4 CY2025 Expectations

RGEN : 125.27 (-2.05%)
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarter Full year 2025 revenue of $738 million, a year-over-year...

RGEN : 125.27 (-2.05%)
Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect

Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect

RGEN : 125.27 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the...

See More

Key Turning Points

3rd Resistance Point 141.41
2nd Resistance Point 134.78
1st Resistance Point 131.33
Last Price 125.27
1st Support Level 121.25
2nd Support Level 114.62
3rd Support Level 111.17

See More

52-Week High 175.77
Fibonacci 61.8% 147.96
Fibonacci 50% 139.37
Fibonacci 38.2% 130.77
Last Price 125.27
52-Week Low 102.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar